Register entry
Intersect ENT, Inc.
- Registered sites
- 1
- Drug products
- 1
- Live patents
- 6
- Countries
- 1
- Base
- United States
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Finished drug manufacture
Sites
Facilities
1| Site | Location | Operations | FEI |
|---|---|---|---|
| Intersect ENT, Inc. | Menlo Park, CAUnited States | Finished drug manufacture | 3008301917 |
Exclusivity
Patents
6Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| SINUVA | MOMETASONE FUROATE | Nov 2026 |
| SINUVA | MOMETASONE FUROATE | Jun 2027 |
| SINUVA | MOMETASONE FUROATE | Oct 2031 |
| SINUVA | MOMETASONE FUROATE | Feb 2032 |
| SINUVA | MOMETASONE FUROATE | Mar 2034 |
| SINUVA | MOMETASONE FUROATE | Nov 2034 |
Catalogue
Marketed products
1Showing 1 of 1.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| Sinuva | mometasone furoate | IMPLANT | NDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.